viewFrontier IP Group PLC

Frontier IP focused on further industrial engagement across portfolio

Neil Crabb says they’re seeing strong interest across the board in their its portfolio

Neil Crabb, chief executive of Frontier IP Group Plc (LON:FIPP) caught up with Proactive's Andrew Scott following the release of their half-year report.

Frontier’s portfolio includes AI drug researcher Exscientia which secured a €15mln strategic investment from drug discovery company Evotec while foodtech company Nandi Protein raised £1mln in the period.

Crabb says they’re seeing strong interest across the board in their its portfolio which he reckons reflects the success of their strategy to take stakes in companies which are at a very early stage of the commercialisation process.

Quick facts: Frontier IP Group PLC

Price: 57.49 GBX

Market: AIM
Market Cap: £29.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...



OneView on course to secure potential Australia Post deal

The AIM Journal's Andrew Hore tells Proactive that OneView Group plc (LON:ONEV) has kicked off a project with the Australian Postal Corporation (Australia Post). Under the contract, OneView will produce a proof of concept of a Sales & Service Platform. Hore also discusses his...

on 3/2/18

2 min read